Wegovy Access Expands to Millions in US on Medicare, Study Finds

Medicare’s recent decision to cover Novo Nordisk A/S’s blockbuster obesity shot Wegovy for heart disease will possibly subsidize the drug for some 3.6 million people, according to a new study from Kaiser Family Foundation.

The US federal health insurance program for people over 65 and those with disabilities has yet to cover Wegovy, or any drug, specifically for weight loss. In March, the US government allowed Novo to market Wegovy for heart disease after a study showed it reduced the risk of heart attacks and strokes by 20%. Later that month, the government agency that runs Medicare told prescription ...